Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07571148 · ClinicalTrials.gov registry record
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
A clinical trial, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 6,876
- Enrollment target
NCT07571148 is a clinical trial that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 6,876 participants.
The verdict
NCT07571148 is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 6,876 participants
- Enrollment target
Study Summary
This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms
Interventions
- DRUG KarXT (xanomeline and trospium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,876 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2026-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07571148
The ClinicalTrials.gov registry entry for NCT07571148 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 6,876 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KarXT (xanomeline and trospium) is the first listed.
NCT07571148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07571148 about?
NCT07571148 is a clinical study titled "Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users". This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visit...
What is the current status of trial NCT07571148?
This trial is currently active not recruiting. The enrollment target is 6,876 participants. The study started on 2026-01-16. Estimated completion is 2026-07-31.
What interventions are being tested in trial NCT07571148?
The interventions under investigation include: KarXT (xanomeline and trospium) (DRUG).
Who is sponsoring clinical trial NCT07571148?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.